Alembic Pharmaceuticals is currently trading at Rs. 409.75, up by 3.20 points or 0.79% from its previous closing of Rs. 406.55 on the BSE.
The scrip opened at Rs. 409.40 and has touched a high and low of Rs. 416.45 and Rs. 409.15 respectively. So far 21649 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 449.70 on 16-Sep-2014 and a 52 week low of Rs. 182.00 on 28-Oct-2013.
Last one week high and low of the scrip stood at Rs. 427.40 and Rs. 400.00 respectively. The current market cap of the company is Rs. 7823.41 crore.
The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 11.12% and 14.76% respectively.
Alembic Pharmaceuticals’ 100% subsidiary Alembic Global Holding has entered into joint venture (JV) deal with Adwiya Mami SARL Algeria. The deal envisages investment by AGH to the extent of 49% equity of Adwiya Mami. Post conclusion of deal the company will be renames as Alembic Mami SPA.
Adwiya Mami owns a state of art formulation plant with a capacity of 1.2 billion per annum oral solids. The plant has been designed and developed by a leading European Pharmaceutical company in line with the cGMP requirements. The plant has enough headroom for future expansion. The investment in Adwiya Mami will give AGH a quick entry to the attractive Algerian market.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.80 |
| Dr. Reddys Lab | 1238.00 |
| Cipla | 1238.25 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2333.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: